Using a tumor model to predict chemo response in pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized approach by growing a miniature model of your tumor from a tissue sample. The goal is to see if this model can predict which chemotherapy will work best for you before you start treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic ductal adenocarcinoma (PDAC) and have not yet received any cancer treatment.
- You are scheduled to receive chemotherapy as a first or later treatment for your stage of cancer (borderline resectable, locally advanced, or metastatic).
- You have at least one tumor that can be measured on scans.
- You are healthy enough to undergo chemotherapy, with normal blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study looks at how your body's chemistry, immune system, and gut bacteria interact during treatment for advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood and stool samples to analyze these factors, hoping to better understand responses to therapy.
This trial uses a lab-grown model of your tumor (called an organoid) to test which drugs might work best for you. It is for people with advanced pancreatic neuroendocrine tumors who cannot have surgery.
This trial tests a method that analyzes your tumor's genes and grows a mini-tumor in a dish to find which drugs might work best for your metastatic pancreatic cancer. It aims to improve treatment choices by using these personalized tests.
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial uses a lab test to see how your tumor responds to different drugs, helping doctors choose the best treatment for you. It is for people with pancreatic cancer (PDAC) who are having surgery or a biopsy.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.